Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Harel, Efrat ^a   Rubinstein, Abraham ^a   Nissan, Aviram ^b   Khazanov, Elena ^a   Milbauer, Mirela ^a   Barenholz, Yechezkel ^a   Tirosh, Boaz ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOLIPOSOME; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; RECEPTOR ANTIBODY; TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIBODY; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; BIOACCUMULATION; CELL PROLIFERATION; CELL STRAIN; CELLULAR DISTRIBUTION; COLITIS; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; CULTURE MEDIUM; ENTERITIS; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; INTERNALIZATION; INTESTINE CELL; LIPOSOMAL DELIVERY; MALE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RAT; TISSUE DISTRIBUTION; ANIMAL; CELL STRAIN CACO 2; CHEMISTRY; COLON; CYTOLOGY; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; IN VITRO STUDY; METABOLISM; MOUSE; WESTERN BLOTTING;

RATTUS;

ANIMALS; ANTIBODIES; BLOTTING, WESTERN; CACO-2 CELLS; CELL PROLIFERATION; COLITIS; COLON; CYTOKINES; ENTEROCYTES; FLOW CYTOMETRY; HUMANS; INFLAMMATORY BOWEL DISEASES; LIPOSOMES; MALE; MICE; RATS; RECEPTORS, TRANSFERRIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052443097     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024202     Document Type: Article

References (50)

1. Baumgart DC, Sandborn WJ, (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657.
2. Targan SR, Shanahan F, Karp LC, (2005) Inflammatory Bowel Disease: From Bench to Bedside New York Springer.
3. Carter MJ, Lobo AJ, Travis SPL, (2004) Guidelines for the management of inflammatory bowel disease in adults. Gut 53: v1-v16.
4. Fiocchi C, (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182-205.
5. Kurtovic J, Segal I, (2004) Recent advances in biological therapy for inflammatory bowel disease. Trop Gastroenterol 25: 9-14.
6. Scholmerich J, Huber G, (2003) Biological therapy in IBD. Anti-tumor necrosis factor-alpha and others. Dig Dis 21: 180-191.
7. Campieri M, (2002) New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut 50 (Suppl 3): III43-III46.
8. Hanauer SB, (2008) Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther 27 (Suppl 1): 15-21.
9. Jubeh TT, Antler S, Haupt S, Barenholz Y, Rubinstein A, (2005) Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. Mol Pharm 2: 2-11.
10. Kesisoglou F, Zimmermann EM, (2005) Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opin Drug Deliv 2: 451-463.
11. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, et al. (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 1352-1355.
12. Jubeh TT, Nadler-Milbauer M, Barenholz Y, Rubinstein A, (2006) Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. J Drug Target 14: 155-163.
13. Jubeh TT, Barenholz Y, Rubinstein A, (2004) Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm Res 21: 447-453.
14. Tirosh B, Khatib N, Barenholz Y, Nissan A, Rubinstein A, (2009) Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol Pharm 6: 1083-1091.
15. Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, et al. (1987) Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 28: 745-753.
16. Tacchini L, Gammella E, De Ponti C, Recalcati S, Cairo G, (2008) Role of HIF-1 and NF-kappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals. J Biol Chem 283: 20674-20686.
17. Huebers HA, Finch CA, (1987) The physiology of transferrin and transferrin receptors. Physiol Rev 67: 520-582.
18. Kawabata H, Yang R, Hirama T, Vuong PT, Kawano S, et al. (1999) Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 274: 20826-20832.
19. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML, (2006) The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121: 144-158.
20. Rodriguez JA, Helguera G, Daniels TR, Neacato II, Lopez-Valdes HE, et al. (2007) Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. J Contr Rel 124: 35-42.
21. Cano E, Pizarro A, Redondo JM, Sanchez-Madrid F, Bernabeu C, et al. (1990) Induction of T cell activation by monoclonal antibodies specific for the transferrin receptor. Eur J Immunol 20: 765-770.
22. Levy JE, Jin O, Fujiwara Y, Kuo F, Andrews NC, (1999) Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat Genet 21: 396-399.
23. Manger B, Weiss A, Hardy KJ, Stobo JD, (1986) A transferrin receptor antibody represents one signal for the induction of IL 2 production by a human T cell line. J Immunol 136: 532-538.
24. Wallace JL, Le T, Carter L, Appleyard CB, Beck PL, (1995) Heptan-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid. J Pharmacol Tox Meth 33: 237-239.
25. Barenholz Y, Amselem S, (1993) Quality control assays in the development and clinical use of liposome-based formulations. In: Gregoriadis G, editors. Liposome Technology 2ed Boca Raton CRC pp. 527-616.
26. Widera A, Norouziyan F, Shen WC, (2003) Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev 55: 1439-1466.
27. Daniels TR, Delgado T, Helguera G, Penichet ML, (2006) The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121: 159-176.
28. Han O, Failla ML, Smith JC, (1997) Transferrin-iron and proinflammatory cytokines influence iron status and apical iron transport efficiency of Caco-2 intestinal cell line. J Nutr Biochem 8: 585-591.
29. Kohen R, Kakunda A, Rubinstein A, (1992) The role of cationized catalase and cationized glucose oxidase in mucosal oxidative damage induced in the rat jejunum. J Biol Chem 267: 21349-21354.
30. Hentze MW, Muckenthaler MU, Galy B, Camaschella C, (2010) Two to tango: regulation of mammalian iron metabolism. Cell 142: 24-38.
31. Kucharzik T, Lugering A, Yan Y, Driss A, Charrier L, et al. (2005) Activation of epithelial CD98 glycoprotein perpetuates colonic inflammation. Lab Invest 85: 932-941.
32. Kim S, Ponka P, (2000) Effects of interferon-gamma and lipopolysaccharide on macrophage iron metabolism are mediated by nitric oxide-induced degradation of iron regulatory protein 2. J Biol Chem 275: 6220-6226.
33. Taetle R, Honeysett JM, (1988) Gamma-interferon modulates human monocyte/macrophage transferrin receptor expression. Blood 71: 1590-1595.
34. Fais S, Delle Fratte F, Mancini F, Cioni V, Guadagno M, et al. (1991) Human cervical epithelial cells that express HLA-DR associated with viral infection and activated mononuclear cell infiltrate. J Clin Pathol 44: 290-292.
35. Fais S, Pallone F, (1989) Ability of human colonic epithelium to express the 4F2 antigen, the common acute lymphoblastic leukemia antigen, and the transferrin receptor. Studies in inflammatory bowel disease and after in vitro exposure to different stimuli. Gastroenterology 97: 1435-1441.
36. Pallone F, Fais S, Capobianchi MR, (1988) HLA-D region antigens on isolated human colonic epithelial cells: enhanced expression in inflammatory bowel disease and in vitro induction by different stimuli. Clin Exp Immunol 74: 75-79.
37. Fais S, Pallone F, Squarcia O, Biancone L, Ricci F, et al. (1987) HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clin Exp Immunol 68: 605-612.
38. Shah D, Shen WC, (1994) The establishment of polarity and enhanced transcytosis of transferrin receptors in enterocyte-like Caco-2 cells. J Drug Target 2: 93-99.
39. Gravotta D, Deora A, Perret E, Oyanadel C, Soza A, et al. (2007) AP1B sorts basolateral proteins in recycling and biosynthetic routes of MDCK cells. Proc Natl Acad Sci U S A 104: 1564-1569.
40. Odorizzi G, Trowbridge IS, (1997) Structural requirements for basolateral sorting of the human transferrin receptor in the biosynthetic and endocytic pathways of Madin-Darby canine kidney cells. J Cell Biol 137: 1255-1264.
41. Forster C, (2008) Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol 130: 55-70.
42. Korzenik JR, Podolsky DK, (2006) Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 5: 197-209.
43. Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, et al. (2005) Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. ScandJ Gastroenterol 40: 1058-1065.
44. Krishna AD, Mandraju RK, Kishore G, Kondapi AK, (2009) An efficient targeted drug delivery through apotransferrin loaded nanoparticles. PLoS One 4: e7240.
45. Barth BM, Sharma R, Altinoglu EI, Morgan TT, Shanmugavelandy SS, et al. (2010) Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano 4: 1279-1287.
46. Faraji AH, Wipf P, (2009) Nanoparticles in cellular drug delivery. Bioorg Med Chem 17: 2950-2962.
47. Ravi Shankaran R, Miura N, (2007) Trends in interfacial design for surface plasmon resonance based immunoassays. J Phys D: Appl Phys 40: 7187-7200.
48. Lai SK, Wang YY, Hanes J, (2009) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61: 158-171.
49. Cu Y, Saltzman WM, (2009) Drug delivery: Stealth particles give mucus the slip. Nat Mater 8: 11-13.
50. Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, et al. (2009) Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci U S A 106: 19268-19273.